Industry Insights

  1. New AAV Reference Standards To Aid CQA Assessment 1/31/2025

    AAVs' complexity makes them difficult analytical testing subjects. The second part of a series describes USP's latest effort to help characterize the viral vectors.

  2. Tracking The Evolution Of CDMO Selection Criteria 2/28/2023

    Year-over-year variation exists in the criteria respondents prioritize in an outsourced manufacturer. Consider these five metrics when choosing a provider for biological drug substance manufacturing.

  3. Relational Risk Analysis For The Bio/Pharma Industry 1/29/2024

    Successfully developing and manufacturing biopharmaceuticals depends on identifying, analyzing, and managing a wide variety of risks. This article presents a novel alternative risk analysis approach that provides a simple, easy, and effective method for quickly and efficiently modeling and analyzing any risk.

  4. Are Plant-Based APIs The Future Of Pharma And Nutraceuticals? 1/29/2025

    As consumer preferences for natural and organic products rise, pharma and nutraceutical companies are increasingly shifting to plant-based APIs. This article shares new market research, including a spotlight on cannabis-based APIs.

  5. Bacteria Media Optimization Using In Silico Strategies 2/21/2024

    Determining ideal media composition for a bacteria is critical because it fosters a satisfactory grow rate, allowing the bacteria to reach the required growth yield.

  6. 5 Questions To Ask Your CDMO: #2 – Can You Tell Me About A Project Where Things Went Wrong? 10/2/2018

    Taking a potential drug from candidate selection through clinical development and eventual commercialization is a challenging process. It is not a question of if something unexpected will happen, but when. And when the inevitable problem occurs, how will your CDMO tackle this situation?

  7. What's Wrong With A Transactional Relationship With Your Contractor? 8/10/2020

    A deal between firms is necessarily an alignment of interests, at least over the term of the deal. There should be no expectation that the interests of two firms will be constant over time or that they will always be able to make a deal or collaborate.

  8. Life Sciences CIO Survey Illuminates Tech Trends 7/15/2022

    Clarkston Consulting recently conducted a CIO Market Study aiming to better understand the current priorities, challenges, and goals of upper-level information technology (IT) professionals. This article delves into the survey results of the life sciences portion of the respondents.

  9. Streamline Early-Stage Development To Reach The Clinic Faster 7/17/2023

    Early-stage development is an iterative process, continuously generating new data and insights to optimize the product based on emerging knowledge.

  10. Identify The Production Strategy Best Suited For Your Protein Or Peptide

    Depending on the protein or peptide of interest for your therapeutic and manufacturing goals, there are a number of different approaches that can prove advantageous. Learn more about these various methods.